Cases – Page 30 – ClaimsFiler

According to the Complaint, Uxin is a used car e-commerce platform in China. The Company has two segments: Uxin Auction (or 2B business) sells used cars to dealers, and Uxin Used Car (or 2C business) sells used cars to consumers.

According to the Complaint, Wirecard, a technology company, purports to provide outsourcing and white label solutions for electronic payment transactions worldwide.

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

According to the Complaint, Arlo provides smart connected devices that can purportedly monitor environments in real-time using its cloudbased platform. This is accomplished by using a Wi-Fi or cellular network Internet connection in the Americas, Europe, the Middle-East, Africa, and the Asia Pacific regions. By using Arlo's cloud-based platform, consumers may engage in real-time with their families and businesses from any location with an internet connection. Arlo also offers Wi-Fi- and LTE-enabled cameras, advanced baby monitors, and smart security lights.

Plaintiff's law firm issued a press release on January 7, 2019, announcing the filing of the lawsuit. According to the press release, Liberty Health Sciences Inc. ("Liberty" or the "Company") was incorporated under the Business Corporations Act (British Columbia) on November 9, 2011, as SecureCom Mobile Inc. The Company's principal business activity is the production and distribution of medical cannabis through its wholly-owned subsidiary DFMMJ LLC (d/b/a Liberty Health Sciences Florida Ltd.). Aphria Inc., which also produces and distributes cannabis, has had long-standing ties with Liberty, starting from the very beginning of both companies.

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

Plaintiff's law firm issued a press release on January 3, 2019 announcing the filing of the Complaint. According to the press release, the Complaint alleges that on December 21, 2018, Perrigo issued a Form 8-K disclosing that the Company had received an audit finding letter from the Irish tax authorities on October 30, 2018 asserting "that IP sales transactions… including the sale of Tysabri®, were not part of the trade of Elan Pharma and therefore should have been treated as chargeable gains subject to an effective 33% tax rate, rather than the 12.5% tax rate applicable to trading income."

According to the Complaint, YRC Worldwide Inc. provides various transportation services primarily in North America. It operates as a holding company with two reporting segments: YRC Freight (longer haul trucking) and Regional Transportation (regional and next-day delivery markets).

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

According to the Complaint, CURO Group Holdings Corp. ("CURO" or the Company) provides short-term credit to underbanked consumers in the United States, the United Kingdom and Canada. In the United States, it operates under two principal brands, "Speedy Cash" and "Rapid Cash." In the United Kingdom, CURO operates online as "Wage Day Advance" and "Juo Loans." In Canada, the Company's stores are branded "Cash Money" and it offers "LendDirect" installment loans online and at certain stores.

According to the Complaint, GreenSky, Inc. ("GreenSky" or the Company) is a financial technology company in Atlanta, Georgia. GreenSky operates an online platform that enables creditors to process loan applications at the point of sale. More than 10,000 businesses are active users of GreenSky's platform. Consumers who seek to make a purchase from such a business can apply for on-the-spot financing via the GreenSky mobile app.

PPDAI Group Inc. (NYSE: PPDF)

According to the Complaint, PPDAI Group Inc. is an online P2P consumer finance company in China and the first online consumer finance marketplace in China connecting borrowers and investors whose needs are unserved or underserved by traditional financial institutions.

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

According to the Complaint, Evoqua purports to be a leading provider of mission critical water treatment solutions,
offering services, systems and technologies to support our customers' full water lifecycle needs. With over 200,000 installations worldwide, the Company holds leading positions in the industrial, commercial and municipal water treatment markets in North America. Evoqua offers a portfolio of differentiated, proprietary technology solutions sold under a number of brands. Evoqua claims that the customer intimacy created through its service network is a significant competitive advantage.

According to the Complaint, Align is a medical device company that purports to design, manufacture, and market products for the treatment of malocclusion or the misalignment of teeth. Invisalign is the proprietary name for the Company's clear aligners.

According to the Complaint, India Globalization Capital, Inc. ("IGC" or the Company) operates two distinct business segments. One segment develops and commercializes cannabinoid based alternative therapies for indications such as Alzheimer's
disease, Parkinson's disease, and pain. The Company's second segment, operated since its inception, is a legacy business that involves trading commodities and heavy equipment rental.

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

According to the Complaint, China Zenix designs, manufactures, and sells commercial vehicle wheels to aftermarket and original equipment manufacturers in the People's Republic of China and internationally. It offers: tubed steel wheels; tubeless steel wheels; off-road steel wheels; aluminum wheels; and wheel components, such as wheel discs.

According to the Complaint, Dycom provides specialty contracting services through subsidiaries throughout the
United States and in Canada. Dycom's services include program management, engineering, construction, maintenance, and installation services for telecommunications providers, underground facility locating services for various utilities, including telecommunications providers, and other construction and maintenance services for electric and gas utilities.

Plaintiff's law firm issued a press release on October 19, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint charges Camping World Holdings, Inc. ("Camping World" or the Company), certain of its officers and directors and controlling shareholders with violations of the Securities Exchange Act of 1934. Historically, the Company specialized in selling recreational vehicles ("RVs") and related services. In October 2016, Camping World went public in a $261 million initial public offering. In the months that followed, Camping World engaged in a number of strategic acquisitions. Most significantly, in May 2017, Camping World announced that it would be expanding its operations to include retail stores for outdoor sporting supplies and accessories by acquiring certain assets of Gander Mountain Co. ("Gander") from bankruptcy.

Sign up today for just $4.99 per month to gain access to full case information AND get real time case monitoring for your investment accounts.

According to the Complaint, Trevena, Inc. ("Trevena" or the Company) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates, including oliceridine (TRV130) to treat moderate to severe acute pain intravenously.

According to the Complaint, Cocrystal Pharma, Inc. ("Cocrystal" or the "Company", f/k/a/ BioZone Pharmaceuticals, Inc.) is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.